Gefitinib companion diagnostic - AstraZeneca/QIAGEN

Drug Profile

Gefitinib companion diagnostic - AstraZeneca/QIAGEN

Alternative Names: Circulating tumour DNA test - AstraZeneca/QIAGEN; Liquid biopsy based gefitinib companion diagnostic - AstraZeneca/QIAGEN; therascreen EGFR RGQ PCR Kit (gefitinib)

Latest Information Update: 15 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator QIAGEN
  • Developer AstraZeneca; QIAGEN
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Non-small cell lung cancer

Most Recent Events

  • 14 Jul 2015 Launched for Non-small cell lung cancer (Diagnosis) in USA (unspecified route)
  • 13 Jul 2015 Launched for Non-small cell lung cancer (Diagnosis) in European Union (unspecified route)
  • 13 Jul 2015 Registered for Non-small cell lung cancer (Diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top